Coretech
In modern pharmaceutical development, scaling chemical syntheses from lab to production remains slow, costly, and risk-prone—driven by manual, trial-and-error development and limited by human intuition.
- Cohort
- NG Autumn 25
- Sector
- Materials & Chemicals · Healthcare & Life Sciences · Industrial & Manufacturing
What they do
Key barriers include:
Product & technology
CoreTech Sciences is a UK spin-out developing a specialised AI platform for the autonomous optimisation of chemical processes. The platform balances productivity and sustainability targets to accelerate process improvement across diverse fields of chemical synthesis. With deep technical foundations, industry validation, and strong partnerships in the biopharmaceutical sector, the company is now positioned to expand into adjacent chemical industries including polymers, materials, and agrochemicals.
Why we invested
- →Big value lever: turns 2-month DoE campaigns into ~2-day cycles, saving millions and pulling drug launch timelines forward.
- →Distinctive tech: closed-loop, hardware-integrated AI that designs, runs and learns from experiments, not just a black-box chemistry model.
- →Strong external proof: £15m+ collaborative funding, AstraZeneca case study (2.5 vs ~8 years dev time) and UK government-backed sustainability projects.
Technology
AI & MLRobotics & Autonomy
Impact
Sustainability
